Siklos® (hydroxyurea) – Expanded indication
On December 7, 2021, the FDA approved Medunik’s Siklos (hydroxyurea), to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
Top